October 25, 2017 — Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference, Oct. 29-Nov. 2 in Denver.
DynamX is a 71-microns-thin metallic DES designed to match the ease of use and acute performance of state-of-the-art DES. Unlike DES, however, DynamX allows the vessel to exhibit its normal pulsatile motion and adaptive remodeling capabilities. Elixir will be sharing for the first time the concept, design, data from preclinical testing and clinical program for its DynamX Stent at a signature evening symposium on Monday, Oct. 30.
Presentation details are below:
Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization: DESappear Study Initial Results with Prava
Thomas Zeller, M.D., Universitäts-Herzzentrum Freiburg, Bad Krozingen, Germany
6 p.m. – 8:00 p.m., Hyatt Regency Centennial Ballroom D-E
For more information: www.elixirmedical.com